Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gabapentin for Chemotherapy-Induced Peripheral Neuropathy
NCT00027963Phase 3Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Feb 2002
- Primary completion
- Nov 2007
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of gabapentin in chemotherapy-induced peripheral neuropathy (CIPN) (2 arms), sponsored by Cancer and Leukemia Group B. Primary endpoint: Change in pain and symptoms at 14 weeks. Started Feb 2002; status: completed.
02
Drugs
gabapentin
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT00027963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00027963.